Oncomed Pharmaceuticals Inc (NASDAQ:OMED) announced that the company has voluntarily halted patient enrollment and dosing in its ongoing Phase 1 clinical trials of its two Wnt pathway inhibitor programs, vantictumab (anti-Fzd7, OMP-18R5) and Fzd8-Fc (OMP-54F28). Oncomed Pharmaceuticals Inc (NASDAQ:OMED) net profit margin is -97.60% and weekly performance is -4.90%. On last trading day company shares ended up $22.71. Analysts mean target price for the company is $44.20. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) distance from 50-day simple moving average (SMA50) is -8.18%.
InterDigital, Inc. (NASDAQ:IDCC) commented on the initial determination by the United States International Trade Commission (“ITC”) in its investigation 337-TA-868 involving Nokia and ZTE. InterDigital, Inc. (NASDAQ:IDCC) shares fell -6.59% in last trading session and ended the day on $45.06. IDCC return on assets is 4.30%. InterDigital, Inc. (NASDAQ:IDCC) quarterly performance is 47.25%.
CytRx Corporation (NASDAQ:CYTR) announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). The updated trial results demonstrated that aldoxorubicin significantly increases progression-free survival (PFS), PFS at 6 months, overall response rate (ORR) and tumor shrinkage, compared to doxorubicin, the current standard-of-care, as a first-line treatment in patients with STS. CytRx Corporation (NASDAQ:CYTR) shares moved down -5.08% in last trading session and was closed at $5.04, while trading in range of $5.01 – $5.46. CytRx Corporation (NASDAQ:CYTR) year to date (YTD) performance is -19.62%.
On 22 MAY Zalicus Inc (NASDAQ:ZLCS) reported successful results from a phase 1 clinical study to evaluate multiple modified-release formulations of Z944, a novel, oral, T-type calcium channel modulator in development for the treatment of pain. The open label, randomized cross-over study compared three modified-release tablet formulations of Z944 with the immediate-release capsule formulation which was shown to be effective in a previous human clinical model of pain. The selected tablet formulation demonstrates a superior exposure and tolerability profile and warrants further clinical development. Zalicus Inc (NASDAQ:ZLCS) ended the last trading day at $1.30. Company weekly volatility is calculated as 11.62% and price to cash ratio as 1.89. Zalicus Inc (NASDAQ:ZLCS) showed a positive weekly performance of 26.21%.
On 2 MAY China Growth Equity Investment Ltd. (NASDAQ:PME) announced that the Company recently ordered 25 newly-built fishing vessels as a continuation of its fleet replacement plan. The vessels have received ratifications from the Ministry of Agriculture of the People’s Republic of China (“MOA”), which ensures that the licenses to fish in foreign waters will be transferred to the new vessels. The Company will retire 25 of its older existing fishing vessels, and the replaced fishing vessels will use new vessel names once put into operations. China Growth Equity Investment Ltd. (NASDAQ:PME) net profit margin is 90.60% and weekly performance is -20.83%. On last trading day company shares ended up $2.47.. China Growth Equity Investment Ltd. (NASDAQ:PME) distance from 50-day simple moving average (SMA50) is -24.06%.